Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042571 (
vertigo
)
7,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mesoporous silica encapsulated Pt (Pt@mSiO
2
) and PtSn (PtSn@mSiO
2
) nanoparticles (NPs) are representatives of a novel class of heterogeneous catalysts with uniform particle size, enhanced catalytic properties, and superior thermal stability. In the ship-in-a-bottle synthesis, PtSn@mSiO
2
intermetallic NPs are derived from Pt@mSiO
2
seeds where the mSiO
2
shell is formed by polymerization of
tetraethyl orthosilicate
around a tetradecyltrimethylammonium bromide template, a surfactant used to template MCM-41. Incorporation of Sn into the Pt@mSiO
2
seeds is accommodated by chemical etching of the mSiO
2
shell. The effect of this etching on the atomic-scale structure of the mSiO
2
has not been previously examined, nor has the extent of the structural similarity to MCM-41. Here, the quaternary Q
2
, Q
3
and Q
4
sites corresponding to formulas Si(O
1/2
)
2
(OH)
2
, Si(O
1/2
)
3
(OH)
1
and Si(O
1/2
)
4
, in MCM-41 and the mesoporous silica of Pt@mSiO
2
and PtSn@mSiO
2
NPs were identified and quantified by conventional and dynamic nuclear polarization enhanced Si-29 Magic Angle
Spinning
Nuclear Magnetic Resonance (DNP MAS NMR). The connectivity of the -Si-O-Si
-
network was revealed by DNP enhanced two-dimensional
29
Si-
29
Si correlation spectroscopy.
...
PMID:Atomic-Scale Structure of Mesoporous Silica-Encapsulated Pt and PtSn Nanoparticles Revealed by Dynamic Nuclear Polarization- Enhanced 29Si MAS NMR Spectroscopy. 3118 24
